This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Novartis Answers Critics

NEW YORK (TheStreet) -- With shares of Merck (MRK), Bristol-Myers Squibb (BMY) and Pfizer (PFE) all trading at or near their 52-week highs, there aren't many bargains left in pharmaceutical stocks. But Novartis (NVS), despite its 32% year-to-date gains, might be a worthwhile exception heading as we head into 2014.

While I do believe threats to the company's pipeline -- specifically from generic competition -- remain valid concerns, I believe the Street has exaggerated fears about margin pressure and the impact it would have on the company's branded drugs business. Given management's recent moves to mitigate pipeline worries, investors would do well by placing a bet here on one of the best names in Big Pharma.

Follow this sector long enough and you will come to appreciate that a company's product pipeline is its lifeblood. If the pipeline is considered weak relative to its peers, the Street will question management's commitment to long term growth, which is often punishable by a low P/E and estimate cuts. This, then, forces the company to push research and development spending higher - in a way to keep its "blood levels up."

As bad as that might appear, the biggest fear, though, is when a company approaches what is called a "patent cliff." This occurs when popular drugs lose their patents, which then opens the floodgates to generic competition, or non-branded alternatives that are often cheaper. Although Novartis has yet to feel adverse effects, the risk to drugs like Diovan, which brings in more than $4 billion in annual sales for Novartis, remains an overhang.

When this happens, and assuming that this expiring patent can't be offset by other strong-selling products within the pipeline, the Street loses faith that the company can support both its current dividend or future cash flow allocations. I don't need to tell you what can happen to a company's stock price. It's not pretty.

Stock quotes in this article: MRK, BMY, PFE, NVS, RHHBY 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs